Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2025)

Vivos Therapeutics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $10.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $10.3 million for Q4 2025, up 104.66% from a year ago — trailing twelve months through Dec 2025 was $10.3 million (up 104.66% YoY), and the annual figure for FY2025 was $10.3 million, up 104.66%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $10.3 million at Vivos Therapeutics, up from $9.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $21.2 billion in Q4 2021 to a low of $849446.0 in Q3 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $7.6 million (2024), against an average of $3.1 billion.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 165977.25% in 2021, then plummeted 100.0% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $21.2 billion in 2021, then crashed by 100.0% to $920592.0 in 2022, then soared by 32.46% to $1.2 million in 2023, then surged by 311.67% to $5.0 million in 2024, then surged by 104.66% to $10.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $10.3 million, $9.6 million, and $9.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.